Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.46 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.45 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8002684 | 0.91 | USP30 (0.44) | MAPTKDM4ETHRBHPGDGPR119 | |
| SCHEMBL24838355 | 0.88 | DDB1 (0.48) | MAPTKDM4ETHRBHPGDGPR119 | |
| SCHEMBL6615022 | 0.87 | HPGD (0.48) | MAPTKDM4ETHRBHPGDGPR119 | |
| SCHEMBL4563256 | 0.86 | NR1H2 (0.44) | MAPTKDM4ETHRBHPGDGPR119 | |
| SCHEMBL27154630 | 0.85 | CTSD (0.43) | MAPTKDM4ETHRBHPGDGPR119 | |
| SCHEMBL994288 | 0.84 | HPGD (0.58) | MAPTKDM4ETHRBHPGDGPR119 | |
| SCHEMBL17128329 | 0.84 | HPGD (0.62) | MAPTKDM4ETHRBHPGDGPR119 | |
| SCHEMBL27669441 | 0.84 | USP2 (0.56) | MAPTKDM4ETHRBHPGDGPR119 | |
| SCHEMBL31028 | 0.84 | USP2 (0.56) | MAPTKDM4ETHRBHPGDGPR119 | |
| SCHEMBL14003333 | 0.83 | HPGD (0.50) | MAPTKDM4ETHRBHPGDGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240246920-A1 | TRIAZOLE DERIVATIVES WITH ANTIFUNGAL ACTIVITY | KING'S COLLEGE LONDON (GB) | 2024-07-25 | — | — | US | disclosed |
| WO-2023239645-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-12-14 | — | — | WO | disclosed |
| US-20230173078-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-06-08 | — | — | US | disclosed |
| WO-2023278402-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-01-05 | — | — | WO | disclosed |
| EP-4100400-A1 | TRIAZOLE DERIVATIVES WITH ANTIFUNGAL ACTIVITY | Kings College London (GB) | 2022-12-14 | — | — | EP | disclosed |
| WO-2021156636-A1 | TRIAZOLE DERIVATIVES WITH ANTIFUNGAL ACTIVITY | KING'S COLLEGE LONDON (GB) | 2021-08-12 | — | — | WO | disclosed |
| CN-102015687-A | Muscarinic receptor agonists, compositions, methods of treatment thereof, and processes for preparation thereof 177 | ASTRAZENECA AB | 2011-04-13 | — | — | CN | disclosed |
| EP-2257543-A1 | MUSCARINIC RECEPTOR AGONISTS, COMPOSITIONS, METHODS OF TREATMENT THEREOF, AND PROCESSES FOR PREPARATION THEREOF 177 | AstraZeneca AB (SE) | 2010-12-08 | — | — | EP | disclosed |
| WO-2009108117-A1 | MUSCARINIC RECEPTOR AGONISTS, COMPOSITIONS, METHODS OF TREATMENT THEREOF, AND PROCESSES FOR PREPARATION THEREOF 177 | ASTRAZENECA AB (SE) | 2009-09-03 | — | — | WO | disclosed |
| WO-2009108117-A1 | MUSCARINIC RECEPTOR AGONISTS, COMPOSITIONS, METHODS OF TREATMENT THEREOF, AND PROCESSES FOR PREPARATION THEREOF 177 | ASTRAZENECA AB (SE) | 2009-09-03 | — | — | WO | disclosed |
| US-20090221567-A1 | MUSCARINIC RECEPTOR AGONISTS, COMPOSITIONS, METHODS OF TREATMENT THEREOF, AND PROCESSES FOR PREPARATION THEREOF 177 | ASTRAZENECA AB (SE) | 2009-09-03 | — | — | US | disclosed |
| US-20090221567-A1 | MUSCARINIC RECEPTOR AGONISTS, COMPOSITIONS, METHODS OF TREATMENT THEREOF, AND PROCESSES FOR PREPARATION THEREOF 177 | ASTRAZENECA AB (SE) | 2009-09-03 | — | — | US | disclosed |
| US-20090221567-A1 | MUSCARINIC RECEPTOR AGONISTS, COMPOSITIONS, METHODS OF TREATMENT THEREOF, AND PROCESSES FOR PREPARATION THEREOF 177 | ASTRAZENECA AB (SE) | 2009-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240246920-A1 | TRIAZOLE DERIVATIVES WITH ANTIFUNGAL ACTIVITY | RIF1, NAT1, POLR1C | MAPT 2424/4885KDM4E 3974/4885THRB 3255/4885 |
| US-20230173078-A1 | SMARCA DEGRADERS AND USES THEREOF | SMARCA1, SMARCA2, SMARCC2 | MAPT 3823/4885KDM4E 223/4885THRB 4304/4885 |
| US-20090221567-A1 | MUSCARINIC RECEPTOR AGONISTS, COMPOSITIONS, METHODS OF TREATMENT THEREOF, AND PROCESSES FOR PREPARATION THEREOF 177 | CHRM1, CHRM2, CHRM3 | MAPT 3044/4885KDM4E 2363/4885THRB 266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.